An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of MHT is associated with superior weight loss outcomes.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% total body weight lost.

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older ...

Boosting Quality of Weight Loss Combining bimagrumab ... Juvena Therapeutics, Kallyope, Metsera, Morphic Medic/GI Dynamics, Novartis, Novo Nordisk, Pfizer, ProSciento, Senda Biosciences, Skye ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

In other recent news, Metsera Inc. has announced positive results from its Phase 1 clinical trial for MET-233i, an amylin analog aimed at treating obesity. The trial revealed up to an 8.4% mean ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another ...